Welcome to our dedicated page for Medpace Holdings news (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings stock.
Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically driven, global, full-service clinical contract research organization (CRO) that regularly issues detailed financial and operational updates. This news page aggregates Medpace news, including quarterly and annual earnings releases, conference call announcements, and other disclosures that matter to investors following MEDP stock and the clinical research sector.
Medpace’s press releases focus on revenue trends, GAAP net income, EBITDA and EBITDA margin, backlog levels, and net new business awards, along with net book-to-bill ratios. The company also provides financial guidance ranges for upcoming periods, discussing expected revenue, net income, and EBITDA, as well as assumptions related to tax rates, interest income, and diluted share counts. These updates help readers understand how demand for Medpace’s Phase I–IV clinical development services is evolving over time.
In addition to earnings results, Medpace frequently announces the dates and times of upcoming earnings releases and conference calls, along with webcast access details and references to supplemental slide presentations in its investors section. The company’s news also touches on capital allocation decisions, such as stock repurchase program authorizations and remaining repurchase capacity, and occasionally on financing arrangements, as reflected in filings related to its unsecured credit facility.
Because Medpace operates as a global CRO serving biotechnology, pharmaceutical and medical device sponsors, its news flow offers insight into the broader outsourcing environment for clinical research and development. Investors, analysts, and industry observers can use this page to review historical announcements, monitor new earnings releases, and track changes in guidance, backlog, and booking trends over time.
Medpace Holdings, Inc. (Nasdaq: MEDP) announced the appointments of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. Geiger, who has been with Medpace since 2007 and previously served as CFO, will focus on driving growth while maintaining strategic oversight. Brady, appointed CFO, has been the executive director of finance since 2018. Both appointments aim to strengthen leadership as Medpace accelerates the global development of medical therapeutics.
Medpace Holdings, Inc. (Nasdaq: MEDP) will announce its second quarter 2021 financial results on July 26, 2021, after market close. A conference call is scheduled for the following morning, July 27, 2021, at 9:00 a.m. ET to discuss the results. Participants can join by dialing 800-219-7113 (U.S.) or 574-990-1030 (international) with passcode 4092073. Webcast access will be available on the Company’s website, where a replay will also be provided. Medpace is a global clinical contract research organization focused on accelerating medical therapeutic development.
Medpace Holdings, Inc. (Nasdaq: MEDP) has announced its participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 9:00 a.m. ET. The event will feature key executives including August Troendle, President & CEO, and Jesse Geiger, CFO & COO. Investors can access the live webcast through the company’s website, with a replay available post-event. Medpace specializes in full-service clinical contract research, focusing on accelerating the development of safe medical therapeutics in various therapeutic areas.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a significant growth in its first quarter 2021 financial results, with revenue rising 12.6% to $260.0 million, up from $230.9 million in Q1 2020. The company achieved a backlog increase of 26.1%, reaching $1.6 billion, and net new business awards totaled $356.2 million, leading to a robust book-to-bill ratio of 1.37x. GAAP net income surged 49.1% to $43.3 million, or $1.14 per diluted share, while EBITDA rose 32.1% to $53.6 million. Medpace also forecasts a revenue increase for 2021 between $1.090 billion and $1.150 billion.
Medpace Holdings, Inc. (Nasdaq: MEDP) will announce its Q1 2021 financial results on April 26, 2021, after market close. A conference call to discuss these results is scheduled for April 27, 2021, at 9:00 a.m. ET. Interested parties can join the call by dialing 800-219-7113 for domestic or 574-990-1030 for international calls, using passcode 8676289. The call will be accessible via webcast on Medpace’s investor website, with a replay available until May 4, 2021. Medpace specializes in Phase I-IV clinical development services for the biotech and pharmaceutical industries.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a strong financial performance for Q4 and the full year 2020, highlighting a 13.0% revenue increase to $259.7 million in Q4 and a 7.5% annual increase to $925.9 million. The company experienced a 20.1% growth in backlog, totaling $1.5 billion. GAAP net income for Q4 was $50.9 million ($1.35 per diluted share), up from $29.8 million in 2019. The 2021 revenue forecast indicates growth of 16.1% to 26.9%. The firm repurchased $47.4 million in shares and had cash equivalents of $277.8 million at year-end.
Medpace Holdings, Inc. (Nasdaq: MEDP) will report its Q4 and fiscal 2020 financial results on February 15, 2021. A conference call will follow on February 16, 2021, at 9:00 a.m. ET, accessible via phone or webcast. Medpace, based in Cincinnati, offers Phase I-IV clinical development services to biotech and pharmaceutical industries, employing around 3,400 staff across 39 countries as of September 30, 2020. The company's focus includes oncology, cardiology, and more, aiming to accelerate the development of safe medical therapeutics.
Medpace Holdings, Inc. (Nasdaq: MEDP) announced a 6.5% increase in third quarter 2020 revenue to $230.4 million compared to $216.2 million in 2019. The net book-to-bill ratio stood at 1.37x with net new business awards of $315.4 million. GAAP net income reached $41.5 million ($1.09 per diluted share), representing an 18.0% net income margin. EBITDA surged by 49.4% to $51.9 million. The company forecasts 2020 revenue between $880 million and $920 million and expects 2021 revenue to range from $1.050 billion to $1.125 billion.